Published in Vaccine Weekly, December 21st, 2005
"Infection with human papillomavirus (HPV) is an absolute prerequisite to development of cervical cancer. Despite early cancer screening by cytological testing, the incidence at approximately 7,000 new cases is still relatively high in comparison to other West European countries."
"The two high-risk HPV types 16 and 18 are responsible for more than 70% of all cases of cervical cancer. So-called 'virus-like particles' can induce a humoral immune response to the HPV envelope protein L1," scientists in Germany report.
"The results of double-blind,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.